Innate Pharma Reports Q1 2026 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IPHA?
Source: seekingalpha
- Cash Position: As of March 31, 2026, Innate Pharma reported cash, cash equivalents, and financial assets totaling €25.4 million, indicating robust liquidity management that supports future R&D and operational needs.
- Financial Liabilities: At the same date, the company's financial liabilities stood at €20.3 million, reflecting a manageable debt level that suggests prudent use of financial leverage, thereby reducing financial risk.
- Significant Revenue Growth: The company achieved revenue of €2.6 million in Q1, representing a 116.7% year-over-year increase, which highlights Innate Pharma's success in market demand and product promotion, potentially laying the groundwork for future profitability.
- Optimistic Market Outlook: With rapid revenue growth and a solid financial position, Innate Pharma's competitive edge in the biopharmaceutical sector is likely to strengthen, attracting more investor interest in its future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IPHA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IPHA
Wall Street analysts forecast IPHA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.420
Low
5.00
Averages
6.50
High
8.00
Current: 1.420
Low
5.00
Averages
6.50
High
8.00
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Innate Pharma Reports Clinical Progress and Financial Update
- Clinical Trial Progress: Innate Pharma plans to initiate the confirmatory Phase 3 TELLOMAK-3 trial for Lacutamab in cutaneous T-cell lymphoma in H2 2026, currently negotiating non-dilutive financing options to support this trial, indicating the company's ongoing commitment in this therapeutic area.
- Drug Safety and Efficacy: IPH4502 (Nectin-4 ADC) has shown a favorable safety profile and preliminary anti-tumor activity in its Phase 1 trial, with the maximum tolerated dose reached and enrollment nearing completion, suggesting significant potential in treating advanced solid tumors.
- Collaborative Research Advancements: The PACIFIC-9 Phase 3 trial, in collaboration with AstraZeneca, is progressing towards a planned data readout in H2 2026, reflecting positive developments in the company's strategic partnerships in non-small cell lung cancer.
- Financial Position: As of March 31, 2026, Innate Pharma reported cash and cash equivalents of €25.4 million, with an anticipated cash runway extending into Q3 2026, demonstrating robust financial management amid ongoing clinical developments.
See More
Innate Pharma Reports Q1 2026 Financial Results
- Cash Position: As of March 31, 2026, Innate Pharma reported cash, cash equivalents, and financial assets totaling €25.4 million, indicating robust liquidity management that supports future R&D and operational needs.
- Financial Liabilities: At the same date, the company's financial liabilities stood at €20.3 million, reflecting a manageable debt level that suggests prudent use of financial leverage, thereby reducing financial risk.
- Significant Revenue Growth: The company achieved revenue of €2.6 million in Q1, representing a 116.7% year-over-year increase, which highlights Innate Pharma's success in market demand and product promotion, potentially laying the groundwork for future profitability.
- Optimistic Market Outlook: With rapid revenue growth and a solid financial position, Innate Pharma's competitive edge in the biopharmaceutical sector is likely to strengthen, attracting more investor interest in its future growth potential.
See More
Innate Pharma Releases Share and Voting Rights Information
- Total Shares Disclosure: As of April 16, 2026, Innate Pharma reports a total of 93,934,210 shares outstanding, including 93,921,863 ordinary shares and 4,766 preferred shares, indicating stability in its capital structure.
- Voting Rights Information: The total theoretical voting rights amount to 93,921,863, with 93,903,288 exercisable voting rights, ensuring market transparency regarding the company's governance structure in compliance with French financial regulations.
- Regulatory Compliance: Innate Pharma's disclosures adhere to the French Commercial Code and AMF regulations, enhancing investor confidence in the company's governance and commitment to market transparency.
- Company Background: Innate Pharma is a global clinical-stage biotechnology firm focused on developing immunotherapies for cancer patients, aiming to address high unmet medical needs, showcasing its innovative potential in the biopharmaceutical sector.
See More
Innate Pharma to Host Q1 2026 Business Update Call
- Conference Call Announcement: Innate Pharma will hold a conference call on May 13, 2026, at 1:30 p.m. CEST to provide a business update for Q1 2026, aiming to enhance investor understanding of the company's progress.
- Executive Participation: The call will feature CEO Jonathan Dickinson and other executives, including Chief Medical Officer Sonia Quaratino, highlighting the leadership's commitment to transparency and communication, which is expected to bolster investor confidence.
- Live Webcast Link: The event will be available via a live webcast, allowing investors to join through the provided link, ensuring broad dissemination of information and reflecting the company's focus on investor relations.
- Replay Availability: A replay of the webcast will be accessible on the company’s website for 90 days post-event, facilitating information access for those unable to attend live, demonstrating the company's commitment to transparency.
See More
Innate Pharma to Participate in Investor Meetings
- Investor Meeting Schedule: Innate Pharma will participate in the D. Boral Capital Global Conference on May 7, 2026, in New York, where its executive team will engage in one-on-one investor meetings aimed at enhancing investor interaction and increasing market visibility.
- Innovative Drug Development: The company is developing a portfolio of immunotherapies for cancer patients, including potential first-in-class or best-in-class assets like IPH4502, lacutamab, and monalizumab, focusing on areas of high unmet medical need, showcasing its innovation in the biotechnology sector.
- Strategic Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca to advance innovation in immuno-oncology, which not only enhances its R&D capabilities but may also accelerate the market introduction of new therapies.
- Global Business Presence: Headquartered in Marseille, France, with an office in Rockville, MD, Innate Pharma's dual listing on Euronext and Nasdaq provides financial support and market recognition for its global business expansion.
See More
Innate Pharma to Participate in Investor Meetings
- Investor Meeting Schedule: Innate Pharma will participate in the D. Boral Capital Global Conference on May 7, 2026, in New York, where members of its executive team will engage in one-on-one meetings with investors, aiming to enhance the company's visibility in the capital markets and attract potential investors.
- Innovative Drug Development: The company is developing several immunotherapies for cancer, including IPH4502, lacutamab, and monalizumab, targeting areas of high unmet medical need, which demonstrates Innate's innovative capabilities and market potential in the biotechnology sector.
- Strategic Partnerships: Innate has established collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca, which not only enhance its R&D capabilities but also provide strong support for the market promotion of its products, further solidifying its position in the field of immuno-oncology.
- Global Business Presence: With its headquarters in Marseille, France, and an office in Rockville, MD, USA, Innate Pharma's international presence allows it to better access global markets, driving the development and commercialization of its innovative drugs.
See More
Innate Pharma Reports Clinical Progress and Financial Update
- Clinical Trial Progress: Innate Pharma plans to initiate the confirmatory Phase 3 TELLOMAK-3 trial for Lacutamab in cutaneous T-cell lymphoma in H2 2026, currently negotiating non-dilutive financing options to support this trial, indicating the company's ongoing commitment in this therapeutic area.
- Drug Safety and Efficacy: IPH4502 (Nectin-4 ADC) has shown a favorable safety profile and preliminary anti-tumor activity in its Phase 1 trial, with the maximum tolerated dose reached and enrollment nearing completion, suggesting significant potential in treating advanced solid tumors.
- Collaborative Research Advancements: The PACIFIC-9 Phase 3 trial, in collaboration with AstraZeneca, is progressing towards a planned data readout in H2 2026, reflecting positive developments in the company's strategic partnerships in non-small cell lung cancer.
- Financial Position: As of March 31, 2026, Innate Pharma reported cash and cash equivalents of €25.4 million, with an anticipated cash runway extending into Q3 2026, demonstrating robust financial management amid ongoing clinical developments.
See More
Innate Pharma Reports Q1 2026 Financial Results
- Cash Position: As of March 31, 2026, Innate Pharma reported cash, cash equivalents, and financial assets totaling €25.4 million, indicating robust liquidity management that supports future R&D and operational needs.
- Financial Liabilities: At the same date, the company's financial liabilities stood at €20.3 million, reflecting a manageable debt level that suggests prudent use of financial leverage, thereby reducing financial risk.
- Significant Revenue Growth: The company achieved revenue of €2.6 million in Q1, representing a 116.7% year-over-year increase, which highlights Innate Pharma's success in market demand and product promotion, potentially laying the groundwork for future profitability.
- Optimistic Market Outlook: With rapid revenue growth and a solid financial position, Innate Pharma's competitive edge in the biopharmaceutical sector is likely to strengthen, attracting more investor interest in its future growth potential.
See More
Innate Pharma Releases Share and Voting Rights Information
- Total Shares Disclosure: As of April 16, 2026, Innate Pharma reports a total of 93,934,210 shares outstanding, including 93,921,863 ordinary shares and 4,766 preferred shares, indicating stability in its capital structure.
- Voting Rights Information: The total theoretical voting rights amount to 93,921,863, with 93,903,288 exercisable voting rights, ensuring market transparency regarding the company's governance structure in compliance with French financial regulations.
- Regulatory Compliance: Innate Pharma's disclosures adhere to the French Commercial Code and AMF regulations, enhancing investor confidence in the company's governance and commitment to market transparency.
- Company Background: Innate Pharma is a global clinical-stage biotechnology firm focused on developing immunotherapies for cancer patients, aiming to address high unmet medical needs, showcasing its innovative potential in the biopharmaceutical sector.
See More
Innate Pharma to Host Q1 2026 Business Update Call
- Conference Call Announcement: Innate Pharma will hold a conference call on May 13, 2026, at 1:30 p.m. CEST to provide a business update for Q1 2026, aiming to enhance investor understanding of the company's progress.
- Executive Participation: The call will feature CEO Jonathan Dickinson and other executives, including Chief Medical Officer Sonia Quaratino, highlighting the leadership's commitment to transparency and communication, which is expected to bolster investor confidence.
- Live Webcast Link: The event will be available via a live webcast, allowing investors to join through the provided link, ensuring broad dissemination of information and reflecting the company's focus on investor relations.
- Replay Availability: A replay of the webcast will be accessible on the company’s website for 90 days post-event, facilitating information access for those unable to attend live, demonstrating the company's commitment to transparency.
See More
Innate Pharma to Participate in Investor Meetings
- Investor Meeting Schedule: Innate Pharma will participate in the D. Boral Capital Global Conference on May 7, 2026, in New York, where its executive team will engage in one-on-one investor meetings aimed at enhancing investor interaction and increasing market visibility.
- Innovative Drug Development: The company is developing a portfolio of immunotherapies for cancer patients, including potential first-in-class or best-in-class assets like IPH4502, lacutamab, and monalizumab, focusing on areas of high unmet medical need, showcasing its innovation in the biotechnology sector.
- Strategic Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca to advance innovation in immuno-oncology, which not only enhances its R&D capabilities but may also accelerate the market introduction of new therapies.
- Global Business Presence: Headquartered in Marseille, France, with an office in Rockville, MD, Innate Pharma's dual listing on Euronext and Nasdaq provides financial support and market recognition for its global business expansion.
See More
Innate Pharma to Participate in Investor Meetings
- Investor Meeting Schedule: Innate Pharma will participate in the D. Boral Capital Global Conference on May 7, 2026, in New York, where members of its executive team will engage in one-on-one meetings with investors, aiming to enhance the company's visibility in the capital markets and attract potential investors.
- Innovative Drug Development: The company is developing several immunotherapies for cancer, including IPH4502, lacutamab, and monalizumab, targeting areas of high unmet medical need, which demonstrates Innate's innovative capabilities and market potential in the biotechnology sector.
- Strategic Partnerships: Innate has established collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca, which not only enhance its R&D capabilities but also provide strong support for the market promotion of its products, further solidifying its position in the field of immuno-oncology.
- Global Business Presence: With its headquarters in Marseille, France, and an office in Rockville, MD, USA, Innate Pharma's international presence allows it to better access global markets, driving the development and commercialization of its innovative drugs.
See More
